Unresectable Metastatic Colorectal Cancer Treatment and Survival – Pauls Stradins Clinical University Hospital Experience

1. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest // J ClinOncol 2007; 25: 1670-1676 Search in Google Scholar

2. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study // J Clin Oncol 2004; 22: 229-37 Search in Google Scholar

3. Ming-ShianT, Yen-HaoS, Ming-Chih H, Jin-Tung L., Tzu-Ping C., Hong-Shiee L., Po-Huang L. Clinicopathological Features and Prognosis in Resectable Synchronous and Metachronous Colorectal Liver Metastasis. // Annals of Surgical Oncology 2007; 14(2):786-794 10.1245/s10434-006-9215-517103254Search in Google Scholar

4. Van Cutsem E, Oliveira J, and on behalf of the ESMO Guidelines Working Group: Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. // Ann Oncol 2009;20: iv61-iv63 10.1093/annonc/mdp13019454465Search in Google Scholar

5. van der Pool AEM, Lalmahomed ZS, Ozbay Y, de Wilt JHW, Eggermont AMM, Jzermans JNM, Verhoef C. ‘Staged’ liver resection in synchronous and metachronouscolorectal hepatic metastases: differences in clinicopathological features and outcome // Colorectal Dis 2010;12(10): e229-35 10.1111/j.1463-1318.2009.02135.x19912286Search in Google Scholar

6. Bockhorn M, Frilling A, Fruhauf NR, Neuhaus J, Molmenti E, Trarbach T, Malago M, Lang H, Broelsch CE. Survival of patients with synchronous and metachronous colorectal liver metastases-is there a difference? // J Gastrointest Surg 2008;12(8):1399- 405 Search in Google Scholar

7. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P. Progression-free survival is a surrogate for survival in advanced colorectal cancer. // J Clin Oncol 2007;25(33):5218-24 10.1200/JCO.2007.11.883618024867Search in Google Scholar

8. Saltz LB, Clarke S, Diaz-Rubio E, Scheitauer W, Figer A, Wong R Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. //J ClinOncol2008;26: 2013-2019 10.1200/JCO.2007.14.993018421054Search in Google Scholar

9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W,Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. //N Engl J Med2004;350: 2335-2342 10.1056/NEJMoa03269115175435Search in Google Scholar

10. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastaticcolorectal cancer. // N Engl J Med 2009; 360(14):1408-17 10.1056/NEJMoa080501919339720Search in Google Scholar

11. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastaticcolorectal cancer. // J ClinOncol 2009; 27(5):663-71 10.1200/JCO.2008.20.839719114683Search in Google Scholar

12. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versusFOLFOX4alone as first-linetreatment in patients with previouslyuntreatedmetastaticcolorectal cancer: the PRIMEstudy. // J ClinOncol 2010;28(31):4697- 705 10.1200/JCO.2009.27.486020921465Search in Google Scholar

13. Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, Brandi G, Martinelli G, Pession A, Pinna AD, Biasco G. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. // Br J Cancer 2008;99: 1729-1734 10.1038/sj.bjc.6604681258495618827815Search in Google Scholar

14. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di SM, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di BM, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C. Phase III randomized trial of FOLFIRI vs FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. // J ClinOncol2005;23: 4866-4875 10.1200/JCO.2005.07.11315939922Search in Google Scholar

15. Etienne-Grimaldi MC, Formento JL, Francoual M, Francois E, Formento P, Renee N, Laurent-Puig P, Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz JF, Milano G. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. // Clin Cancer Res 2008;14: 4830-4835 10.1158/1078-0432.CCR-07-490618676755Search in Google Scholar

16. Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, Mignard D, Awad L, Herait P, Culine S, Trillet-Lenoir V. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. // Br J Cancer 2000;83: 431- 437 10.1054/bjoc.2000.1303237466310945486Search in Google Scholar

17. Mekenkamp JM, Koopman M, Teerenstra S, van Krieken JHJM, Mol L, Nagtegaal ID, Punt CJA. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. // Br J Cancer2010;103(2): 159-164. 10.1038/sj.bjc.6605737290673320551951Search in Google Scholar